A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

BACKGROUND: Synovial Sarcomas (SS) are rare tumors occurring predominantly in adolescent and young adults with a dismal prognosis in advanced phases. We report a first-in-human phase I of monoclonal antibody (OTSA-101) targeting FZD10, overexpressed in most SS but not present in normal tissues, labe...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraudet, Anne-Laure, Cassier, Philippe Alexandre, Iwao-Fukukawa, Chicaco, Garin, Gwenaelle, Badel, Jean-Noël, Kryza, David, Chabaud, Sylvie, Gilles-Afchain, Laurence, Clapisson, Gilles, Desuzinges, Claude, Sarrut, David, Halty, Adrien, Italiano, Antoine, Mori, Masaharu, Tsunoda, Takuya, Katagiri, Toyomasa, Nakamura, Yusuke, Alberti, Laurent, Cropet, Claire, Baconnier, Simon, Berge-Montamat, Sandrine, Pérol, David, Blay, Jean-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994021/
https://www.ncbi.nlm.nih.gov/pubmed/29884132
http://dx.doi.org/10.1186/s12885-018-4544-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994021/
https://www.ncbi.nlm.nih.gov/pubmed/29884132
http://dx.doi.org/10.1186/s12885-018-4544-x

Ejemplares similares